Healthtech Series B Investors & VC Firms
1216 firms in this list, with a median first check of $750K. 285 of them lead rounds. Generated from verified public data and updated continuously.
Oxford Investment Consultants LLP
OxfordSeed–Late Stage
11 people
Cancer Fund
PhoenixSeed–Series C
9 people
Cobalt Ventures
Kansas CitySeries A–Series B$10M – $75M
6 people
NGEN Partners
New YorkSeed–Growth$5M – $20M
3 people
Utiliti Group
SydneySeed–Late Stage
SeedToB
SuwaneePre-Seed–Series B$500K – $1.5M
5 people
Pandect Bioventures
WoodsideSeed–Late Stage
10 people
YZR Capital
MunichPre-Seed–Growth
6 people
AI Capital
DenverSeries A–Growth
11 people
Georgian
Toronto, OntarioSeries B–Late Stage$25M – $100M
11 people
OCV Partners
Los AngelesPre-Seed–Late Stage
5 people
Transcend Capital Partners
Hong KongPre-Seed–Series B$2.5M – $5M
8 people
Vesalius Biocapital Partners
LuxembourgSeed–Late Stage$11M
5 people
Healthier Capital
Menlo ParkSeed–Series B
6 people
Shenzhen Capital Group
ShenzhenSeed–Growth$1.5M – $156M
3 people
Catalyst Romania
BucharestSeed–Growth$1.2M – $3.6M
5 people
Esplanade Ventures
TorontoPre-Seed–Series B
11 people
Finchley Healthcare Ventures
MontrealSeed–Late Stage
11 people
i&i Biotech Fund
PraguePre-Seed–Series B$150K – $2M
8 people
IPD Capital
AventuraSeed–Series B
5 people
N-Vest Venture
BangkokPre-Seed–Late Stage$1M – $7.4M
8 people
naturalX Health Ventures
KarlsruheSeed–Late Stage$3.2M – $5.4M
5 people
Panakes Partners
MilanSeed–Late Stage
11 people
Sirius Venture Partners GmbH
WiesbadenSeed–Growth$540K – $5.4M
8 people
Related lists
Series B Investors & VC Firms (4094)Healthtech Investors & VC Firms (3208)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Series B Investors & VC Firms in United States (1625)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)
Data sourced from public filings and firms' own websites — see our methodology.






























































